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Purpose: The majority of people with type 2
diabetes mellitus (T2DM) will develop chronic kidney
disease in their lifetime. Because most dipeptidyl
peptidase (DPP)-4 inhibitors require dose adjustment
in patients with T2DM and renal impairment, we
aimed to understand how these treatments are pre-
scribed in UK clinical practice, and to determine
whether recommended dose adjustments are being
made at initial prescription.
Methods: This retrospective, descriptive cohort
study analyzed data from the Clinical Practice Re-
search Datalink (CPRD). Patients of interest were
those with T2DM and renal impairment initiated on
a DPP-4 inhibitor between 2014 and 2015. Patients
under 40 years of age and with type 1 diabetes were
excluded. Descriptive statistics were calculated for
baseline demographic and clinical characteristics,
and the study protocol was approved by the Inde-
pendent Scientiﬁc Advisory Committee for Medicines
and Healthcare products Regulatory Agency database
research.
Findings: A total of 3425 patients diagnosed with
T2DM and renal impairment and initiated on a DPP-4
inhibitor were identiﬁed. The percentages of patients
prescribed the high dose of saxagliptin, alogliptin,
sitagliptin, and vildagliptin were 48%, 43%, 41%,
and 27%, respectively, which is not recommended*Current afﬁliation: Celgene Ltd, London, United Kingdom.
†Current afﬁliation: Pﬁzer, Surrey, United Kingdom.
‡Current afﬁliation: No current afﬁliation; most recent (until
the end of January) was Boehringer Ingelheim Ltd, Berkshire,
United Kingdom.
August 2016given their renal dysfunction. These are conservative
estimates, as they do not include patients with severe
renal impairment on sitagliptin and alogliptin, whose
doses should be further reduced. No patients were
prescribed an inappropriately high dose of linagliptin,
as there is no requirement for dose adjustment in
patients with renal impairment.
Implications: In this study, a considerable number
of patients with T2DM and renal impairment were
prescribed an inappropriately high dose of saxagliptin,
alogliptin, sitagliptin, or vildagliptin for their level of
renal impairment at treatment initiation. This pre-
scribing could have been due to the complexity of
different dosing requirements, or a lack of awareness
of the need for dose adjustment of most DPP-4
inhibitors in patients with renal impairment. Linaglip-
tin may be used in patients with moderate or severe
renal impairment without dose adjustment. (Clin
Ther. 2016;38:1825–1832) & 2016 The Authors.
Published by Elsevier HS Journals, Inc.
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diabetes mellitus.INTRODUCTION
The association between type 2 diabetes mellitus
(T2DM) and renal impairment is well-established,Accepted for publication July 11, 2016.
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Clinical Therapeuticswith several studies reporting the increased risk for
renal failure in patients with T2DM.1–4 UK-based
studies suggest that people with T2DM have a 4.5- to
6-fold increased risk for developing moderate to
severe chronic kidney disease.5 Diabetes is also the
leading cause of end-stage renal disease in the United
Kingdom,6 and 30% of people with T2DM have
clinically signiﬁcant renal impairment.4,6
A number of commonly used antidiabetic medica-
tions are not recommended in individuals with mod-
erate7 or severe8,9 renal impairment (estimated
glomerular ﬁltration rate [eGFR] o60 mL/min/1.73
m2). For example, metformin and the sulfonylureas,
which are recommended as ﬁrst-line treatments
by the National Institute for Health and Care Ex-
cellence, should be used with caution in patients with
renal impairment.10 Newer classes of antidiabetic
medicines have now been licensed for the treatment
of T2DM, including dipeptidyl peptidase (DPP)-4
inhibitors. These agents give clinicians and patients
more options in the management of T2DM.
Five drugs are available within the DPP-4 inhibitor
class: alogliptin, linagliptin, saxagliptin, sitagliptin,
and vildagliptin.
While DPP-4 inhibitors offer more ﬂexibility for
patients with renal impairment, each member of the class
requires a different level of dose adjustment depending on
kidney function (Table I 11–15). Sitagliptin,11 saxagliptin,14
vildagliptin,13 and alogliptin12 require different dosing
strategies if patients have moderate to severe renal impair-
ment. Linagliptin does not require dose adjustment in
these patients, as it is excreted via the bile and feces, withTable I. Thresholds for dose adjustment.
Drug
Level
CrCl Z50 mL/min CrCl 30–o50
Sitagliptin11 100 mg 50 m
Alogliptin12 25 mg 12.5 m
Vildagliptin13 50 mg BID
Saxagliptin14 5 mg
Linagliptin15
CrCl ¼ creatinine clearance; ESRD = end-stage renal disease.
*Except saxagliptin, which is not recommended for use in patien
1826o5% excreted via the kidneys.15 The different
requirements mean that there is a risk that some
patients with T2DM and renal impairment may not be
prescribed a recommended dose according to their level of
renal impairment. There is thus a need to review the doses
of DPP-4 inhibitors prescribed to these patients, in
comparison with the recommendations in the summary
of product characteristics (SPC) of each medicine.
In addition, the National Institute for Health and
Care Excellence recently updated its clinical guideline
on T2DM.10 As such, it would also be useful to
describe the characteristics of patients with T2DM
treated with DPP-4 inhibitors, as well as how these
characteristics are used in the treatment pathway, to
compare clinical practice with the new guidelines.
The observational data available in the Clinical
Practice Research Datalink (CPRD) are representative
of routine primary care in the United Kingdom, and
therefore provide a way of gaining insight into both
patient characteristics and adherence to guidelines in
the treatment of T2DM in the United Kingdom.16MATERIALS AND METHODS
Study Design
This retrospective, descriptive cohort study ana-
lyzed data from patients with T2DM and renal
impairment who were initially prescribed a DPP-4
inhibitor. The drug and dosage prescribed, as well as
the appropriateness of this prescription based on each
patient’s level of renal impairment, were then eval-
uated based on the ﬁrst DPP-4 inhibitor prescribed.of Renal Impairment
mL/min CrCl o30 mL/min (Including ESRD*)
g 25 mg
g 6.25 mg
50 mg once daily
2.5 mg
All Levels of Renal Impairment
5 mg
ts with end-stage renal disease requiring hemodialysis.
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agreement between the prescription and the dose
recommendations in the SPC.
All data were extracted from the CPRD, a database
of anonymized, longitudinal clinical records from
general practice that contains information on the
demographic characteristics, diagnoses, referrals, pre-
scriptions, and health outcomes of patients from 689
general practitioners’ practices in the United King-
dom. It is a well-validated database, with several
studies conﬁrming the high quality of the data and
the completeness of the clinical records.16–19 The
quality of the database is reﬂected in the number of
studies published using CPRD data, which currently
stands at over 1500.20 There were 14 million patients
of "acceptable" standard for research in the CPRD at
the time of data extraction for this study (July 2015).
Exposures and Covariates
The study included data from patients with a
diagnostic code for T2DM and who were registered
with a practice that met the minimum requirements
for data quality. Patients must also have had a
prescription for a DPP-4 inhibitor, with their ﬁrst
prescription between January 1, 2014 and May 31,
2015. Six months’ history before the ﬁrst prescription
of a DPP-4 inhibitor was also required.
Patients were excluded if they were under 40 years
of age at the time of diabetes diagnosis, or if they were
recorded as having type 1 diabetes mellitus. Codes
used to identify T2DM diagnosis and prescriptions of
DPP-4 inhibitors are available in Supplemental
Appendixes A and B in the online version at http://
dx.doi.org/10.1016/j.clinthera.2016.07.006.
Data from a subset of the overall cohort, patients
with T2DM and renal impairment who had a pre-
scription for a DPP-4 inhibitor, were then investigated.
Outcomes
Patients’ baseline characteristics of interest included
the number of patients with T2DM and a prescription
for a DPP-4 inhibitor, the age of these patients at the
ﬁrst prescription of a DPP-4 inhibitor, time since
T2DM diagnosis, and history of use of antidiabetic
medications and comorbidities (PVD, AF, renal
failure, myocardial infarction, congestive heart failure,
stroke, blindness, moderate to severe renal impair-
ment, and amputation). The Read codes used can be
found in Supplemental Appendix C in the onlineAugust 2016version at http://dx.doi.org/10.1016/j.clinthera.2016.
07.006.
The outcomes of interest in the group of patients
with T2DM, renal impairment, and a prescription for
a DPP-4 inhibitor were as follows.
Drug and Dosage Prescribed (Based on the First
Prescription of a DPP-4 Inhibitor)
Drugs and doses of interest included alogliptin (25,
12.5, and 6.25 mg), linagliptin (5 mg), saxagliptin (5
and 2.5 mg), sitagliptin (100, 50, and 25 mg), and
vildagliptin (50 mg BID and once daily).
Level of Renal Impairment
Within the analysis, we utilized 2 methods to
identify renal impairment in the CPRD: using (1)
Read codes or (2) the results of serum creatinine tests
(serum creatinine test results were used to calculate the
eGFR, via the Modiﬁcation of Diet in Renal Disease
study equation). The deﬁnition of moderate or severe
renal impairment used in this study was a Read code
of renal impairment of stage 3/3a/3b/4/5 or a calcu-
lated eGFR (based on serum creatinine value) of o60
mL/min/1.73 m2. This deﬁnition was chosen for
consistency between the Read codes and eGFR results,
although it does not capture the different requirements
for dose adjustment for every DPP-4 inhibitor (Table I).
The ﬁnal cohort of patients of interest therefore had a
code for T2DM, a prescription for a DPP-4 inhibitor,
and a relevant Read code for renal impairment and/or
an eGFR o60 mL/min/1.73 m2.
Statistical Analysis
Data were extracted using the online version of
CPRD-GOLD and were analyzed using SAS software
version 9.4 (SAS Institute, Cary, North Carolina).15
The study was primarily descriptive, with no
hypothesis testing; therefore, power calculations
were not conducted. Descriptive statistics were
calculated for the baseline demographic and clinical
characteristics.
Ethics Approval
The study protocol was reviewed and approved by
the Independent Scientiﬁc Advisory Committee for
Medicines and Healthcare products Regulatory Agency
database research (reference number 15_184Mn), and
an internal scientiﬁc committee within the sponsoring
company.1827
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Patients’ Baseline Characteristics
A total of 11,959 patients with T2DM and a
prescription for a DPP-4 inhibitor (6725 prescribed
sitagliptin, 2998 prescribed linagliptin, 1669 prescribed
saxagliptin, 434 prescribed alogliptin and 133 prescribed
vildagliptin) were recorded in the CPRD. The mean age
at the time of diagnosis was 65.0 years, the mean
duration of T2DM was 9.0 years, and the mean HbA1c
level was 8.32%. There were similar numbers of men and
women included in the study.
Patients prescribed the higher doses of sitagliptin,
saxagliptin, and alogliptin had lower mean ages, had
shorter durations of diabetes, and were more likely to
be men compared with the overall population. They
also tended to have higher HbA1c levels. Patients with
more comorbidities were more likely to have been
prescribed lower doses. A total of 11% of the patients
prescribed the highest dose of sitagliptin had moderate
or severe renal impairment, compared with 48% for
the lowest dose. The corresponding ﬁgures for sax-
agliptin, vildagliptin, and alogliptin were 16% versus
59%, 11% versus 39%, and 9% versus 48%,
respectively.
The baseline characteristics of the patients included
in the study are shown in Table II.
Treatment Pathway
All antidiabetic medications that were identiﬁed from
patients’ medical records as having been prescribed
before the ﬁrst prescription of a DPP-4 inhibitor were
analyzed as a part of this study. Metformin was the
most commonly prescribed antidiabetic therapy used
before DPP-4 inhibitor initiation, followed by sulfony-
lureas, thiazolidinediones, and insulin (Table III). Only a
small proportion of patients were prescribed an SGLT-2
inhibitor before a DPP-4 inhibitor. However, prior
insulin use was not uncommon: 17% of linagliptin
patients were prescribed insulin before the prescription
of linagliptin. These ﬁgures were 8% to 16%, 7% to
12%, 7%, and 0% to 6% with saxagliptin, sitagliptin,
vildagliptin, and alogliptin, respectively.
Prescribed Doses of DPP-4 Inhibitors
Of the patients prescribed DPP-4 inhibitors, 3425
(29%) had renal impairment before the point of
treatment initiation. Table IV shows the number and
percentages of patients who had renal impairment at
DPP-4 inhibitor prescription. Totals of 1578 (53%),18281317 (20%), 424 (25%), 76 (18%), 30 (23%) of
patients prescribed linagliptin, sitagliptin, saxagliptin,
alogliptin, and vildagliptin, respectively, had moderate
to severe renal impairment (based on either Read code
or eGFR). A number of these patients had been
prescribed higher doses of medication, which were
inappropriate for their level of kidney function. Of the
patients with renal impairment, 48%, 43%, 41%, and
27% prescribed saxagliptin, alogliptin, sitagliptin, and
vildagliptin were on a potentially inappropriately high
dose. Because no dose adjustment is required for
linagliptin,15 none of the patients were prescribed an
inappropriate dose of linagliptin based on kidney
function.DISCUSSION
Treatment Pathway
The present study found that metformin was the
most common historical treatment for patients with
T2DM, being used in 79% to 98% of patients before
their DPP-4 inhibitors. This is unsurprising, as metfor-
min is recommended as ﬁrst-line therapy in a number of
current guidelines.10,21 although it is contraindicated or
to be used with caution in patients with moderate or
severe renal impairment.7,22 More interesting is the
number of patients who had been prescribed insulin
before a DPP-4 inhibitor, which is different from the
pathway given in the most recent clinical guideline from
the National Institute for Health and Care Excellence.10
This guideline recommends that insulin be initiated after
oral anti-diabetic medications, including monotherapy
and combination therapy, have been considered.
Prescription of Inappropriate Doses of DPP-4
Inhibitors
This analysis shows that considerable numbers of
patients with T2DM and renal impairment were
initially prescribed inappropriately high doses of
DPP-4 inhibitors, based on the recommendations in
the SPCs, with almost half of the patients with renal
impairment prescribed sitagliptin, saxagliptin, and
alogliptin. This estimate is conservative, as it does
not include patients with severe renal impairment on
sitagliptin and alogliptin, whose doses should be
further reduced. The numbers of patients prescribed
inappropriately high doses of DPP-4 inhibitors suggest
that this occurrence is common in current clinical
practice. The proportions of patients with moderate orVolume 38 Number 8
Table II. Baseline characteristics.
Sitagliptin
Linagliptin
5 mg
(n ¼ 2998)
Vildagliptin
50 mg (n ¼ 133)
Saxagliptin Alogliptin
100 mg
(n ¼ 5001)
50 mg
(n ¼ 1192)
25 mg
(n ¼ 532)
5 mg
(n ¼ 1295)
2.5 mg
(n ¼ 374)
25 mg
(n ¼ 354)
12.5 mg
(n ¼ 53)
6.25 mg
(n ¼ 27)
Age at the time of
prescription,
mean (SD), y
61.3
(12.1)
68.3 (12.7) 68.8 (13.5) 62.6 (12.1) 69.8
(12.8)
62.0
(10.7)
70.4
(13.0)
68.3
(13.9)
Male, % 59 53 49 55 53 58 51 60 49 52
Diabetes duration,
mean, y
7.9 10.1 10.2 10.4 9.1 8.2 10.9 8.5 11.3 11.5
HbA1c , mean, % 8.5 8.4 8.3 8.4 7.9 8.4 8.3 8.5 8.8 8.7
Comorbidity, %
Moderate or
severe renal
impairment
11 44 48 53 23 16 59 9 57 48
MI 6 8 10 10 7 7 10 6 4 4
Stroke 4 5 8 6 9 4 7 2 8 4
AF 5 9 12 12 7 6 11 6 8 7
PVD 3 5 6 7 2 3 8 3 6 0
CHF 2 8 11 9 4 3 10 2 9 4
Amputation 1 1 1 2 4 1 1 1 0 0
Blindness 0 1 2 1 0 0 1 1 0 0
Renal failure 0 0 0 1 0 0 0 0 2 4
AF ¼ atrial ﬁbrillation; CHF ¼ congestive heart failure; HbA1c ¼ hemoglobin A1c; MI ¼ myocardial infarction; PVD ¼ peripheral vascular disease.
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Table III. History of use of antidiabetic medications. Data are given as % of patients.
Treatment
Sitagliptin
Linagliptin
5 mg
(n ¼ 2998)
Vildagliptin
50 mg
(n ¼ 133)
Saxagliptin Alogliptin
100 mg
(n ¼ 5001)
50 mg
(n ¼ 1192)
25 mg
(n ¼ 532)
5 mg (n
¼ 1295)
2.5 mg (n
¼ 374)
25 mg (n
¼ 354)
12.5 mg
(n ¼ 53)
6.25 mg
(n ¼ 27)
Metformin 90 92 89 89 79 92 89 97 98 96
SU 65 67 67 62 63 54 63 58 75 67
TZD 15 21 20 21 12 14 22 18 15 26
SGLT-2i 2 2 1 2 2 4 3 7 2 0
Insulin 7 10 12 17 7 8 16 6 6 0
SGLT-2i ¼ sodium glucose cotransporter-2 inhibitor; SU ¼ sulfonylurea; TZD ¼ thiazolidinedione.
Clinical Therapeuticssevere renal impairment who were prescribed inap-
propriately high doses were also relatively consistent
across all DPP-4 inhibitors, with the exception of
linagliptin, suggesting that this affects the majority of
the class.
The present study also identiﬁed some patients
prescribed the lowest doses of DPP-4 inhibitors who
did not have moderate or severe renal impairment
(61% of patients prescribed vildagliptin 50 mg once
daily; 52%, sitagliptin 25 mg; 52%, alogliptin 6.25Table IV. Renal impairment at treatment initiation.
Drug Dose*
Moderate or Sever
Impairment, no.
Sitagliptin 100 mg (n ¼ 5001) 539 (11)
50 mg (n ¼ 1192) 523 (44)
25 mg (n ¼ 532) 255 (48)
Linagliptin 5 mg (n ¼ 2998) 1578 (53)
Vildagliptin 50 mg BID (n ¼ 76) 8 (11)
50 mg once daily
(n ¼ 57)
22 (39)
Saxagliptin 5 mg (n ¼ 1295) 203 (16)
2.5 mg (n ¼ 374) 221 (59)
Alogliptin 25 mg (n ¼ 354) 33 (9)
12.5 mg (n ¼ 53) 30 (57)
6.25 mg (n ¼ 27) 13 (48)
eGFR ¼ estimated glomerular ﬁltration rate.
*n ¼ patients in the Clinical Practice Research Datalink with a
†Deﬁned as eGFR o60 mL/min/1.73 m2 or a Read code of sta
1830mg; and 41%, saxagliptin 2.5 mg). According to SPC
recommendations, these doses are also inappropriate,
as adjustment is not required in patients with mild
renal impairment. These ﬁndings, in combination with
the numbers of patients with renal failure who were
prescribed inappropriately high doses, suggest that
there is confusion or a lack of awareness around the
different requirements for dose adjustments for each
DPP-4 inhibitor, although this study does not allow us
to make ﬁrm conclusions on this.e Renal
† (%)
Patients with Renal Failure on an
Inappropriate Dose, %
41
0
27
48
43
prescription for each DPP-4 inhibitor.
ge 3/3a/3b/4/5 kidney disease.
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proportion of patients with renal impairment, possibly
reﬂecting the simple dosing strategy of one dose that is
appropriate for all levels of renal function. However,
of the patients prescribed linagliptin, the number
without renal impairment was similar to the number
with renal impairment (47% vs 53%), suggesting that
linagliptin is used across the population with T2DM
regardless of kidney function. The corresponding
ﬁgures for the other DPP-4 inhibitors were less
balanced (alogliptin, 82% without renal impairment
vs 18% with renal impairment; sitagliptin, 80% vs
20%; vildagliptin, 77% vs 23%; and saxagliptin,
75% vs 25%).
Alternative Methodologies Considered and Study
Limitations
An alternative research methodology, patient record
auditing through gaining access to general practitioners’
practice records, was considered. However, this ap-
proach was rejected, as it would have been unlikely to
achieve the same level of coverage as analysis of data
from the CPRD database.
However, the use of data from the CPRD may have
led to certain study limitations, particularly around
the availability of data. For instance, the date of
diagnosis of T2DM is often recorded months or even
years after the actual onset of the disease; therefore,
the date of the ﬁrst record of T2DM can be used only
as a proxy. The CPRD also provides information on
prescribed, rather than dispensed, medications. It is
therefore possible that patients may have been pre-
scribed medications that were not collected or used.
In addition, only patients with renal impairment
before the initiation of a DPP-4 inhibitor were consid-
ered for analysis. Since patients with T2DM tend to
experience worsening renal function as the disease
progresses, it is likely that the numbers of patients
treated with an inappropriate dose of DPP-4 inhibitors
were underestimated. Since the study considered only
initial prescriptions, and information on the duration of
treatment was not collected, it was not possible to
determine whether patients’ dosages were adjusted at a
later date.CONCLUSIONS
Our study suggests that patients with T2DM
and renal impairment are commonly prescribed anAugust 2016inappropriately high initial dose of saxagliptin, alog-
liptin, sitagliptin, or vildagliptin, based on the recom-
mendations in the SPCs. The ﬁndings highlight the
need to raise awareness around the requirements for
dose adjustment of all DPP-4 inhibitors except lina-
gliptin when used in patients with moderate or severe
renal impairment.ACKNOWLEDGMENTS
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Tables A.1, B.1, C.1.Table A.1. Product codes for DPP-4 inhibitors
Prodcode Product Name
Alogliptin
59809 Alogliptin 6.25mg tablets
60328 Alogliptin 12.5mg tablets
59177 Alogliptin 25mg tablets
Linagliptin
46665 Linagliptin 5mg tablets
46716 Trajenta 5mg tablets
Saxagliptin
41204 Saxagliptin 5mg tablets
45775 Saxagliptin 2.5mg tablets
41431 Onglyza 5mg tablets
45821 Onglyza 2.5mg tablets
Sitagliptin
50087 Januvia 50mg tablets
48533 Sitagliptin 25mg tablets
35462 Januvia 100mg tablets
50124 Januvia 25mg tablets
48401 Sitagliptin 50mg tablets
35022 Sitagliptin 100mg tablets
Vildagliptin
39149 Galvus 50mg tablets
60682 Vipidia 25mg tablets
62326 Vipidia 6.25mg tablets
37875 Vildagliptin 50mg tablets
60681 Vipidia 12.5mg tabletsAugust 2016 1832.e1
Table B.1. T2DM medical codes
Pegasus Code Read Code Read Term
758 C10F.00 Type 2 diabetes mellitus
506 C100112 Non-insulin dependent diabetes mellitus
4513 C109.00 Non-insulin dependent diabetes mellitus
17859 C109.12 Type 2 diabetes mellitus
1407 C10FJ00 Insulin treated Type 2 diabetes mellitus
18219 C109.13 Type II diabetes mellitus
18390 C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria
5884 C109.11 NIDDM - Non-insulin dependent diabetes mellitus
18278 C109J00 Insulin treated Type 2 diabetes mellitus
26054 C10FL00 Type 2 diabetes mellitus with persistent proteinuria
12640 C10FC00 Type 2 diabetes mellitus with nephropathy
22884 C10F.11 Type II diabetes mellitus
18496 C10F600 Type 2 diabetes mellitus with retinopathy
8403 C109700 Non-insulin dependant diabetes mellitus - poor control
25627 C10F700 Type 2 diabetes mellitus - poor control
32627 C10FN00 Type 2 diabetes mellitus with ketoacidosis
34912 C109400 Non-insulin dependent diabetes mellitus with ulcer
47954 C10F900 Type 2 diabetes mellitus without complication
34450 C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus
36695 C10D.00 Diabetes mellitus autosomal dominant type 2
29979 C109900 Non-insulin-dependent diabetes mellitus without complication
34268 C10F200 Type 2 diabetes mellitus with neurological complications
53392 C10F911 Type II diabetes mellitus without complication
18777 C10F000 Type 2 diabetes mellitus with kidney complications
35385 C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy
25591 C10FQ00 Type 2 diabetes mellitus with exudative maculopathy
17262 C109600 Non-insulin-dependent diabetes mellitus with retinopathy
18425 C10FB00 Type 2 diabetes mellitus with polyneuropathy
60796 C10FL11 Type II diabetes mellitus with persistent proteinuria
49074 C10F400 Type 2 diabetes mellitus with ulcer
41389 C105100 Diabetes mellitus, adult onset, þ ophthalmic manifestation
63762 C10z100 Diabetes mellitus, adult onset, þ unspeciﬁed complication
44982 C10FE00 Type 2 diabetes mellitus with diabetic cataract
50609 L180600 Pre-existing diabetes mellitus, non-insulin-dependent
59365 C109C00 Non-insulin dependent diabetes mellitus with nephropathy
46917 C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma
47321 C10F100 Type 2 diabetes mellitus with ophthalmic complications
62674 C10FA00 Type 2 diabetes mellitus with mononeuropathy
47315 C10F711 Type II diabetes mellitus - poor control
18264 C109J12 Insulin treated Type II diabetes mellitus
24458 C109711 Type II diabetes mellitus - poor control
12736 C10F500 Type 2 diabetes mellitus with gangrene
36633 C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus
63690 C10FR00 Type 2 diabetes mellitus with gastroparesis
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Pegasus Code Read Code Read Term
64668 C10FJ11 Insulin treated Type II diabetes mellitus
45913 C109712 Type 2 diabetes mellitus - poor control
51756 C10FP00 Type 2 diabetes mellitus with ketoacidotic coma
58604 C109611 Type II diabetes mellitus with retinopathy
49655 C10F611 Type II diabetes mellitus with retinopathy
37806 C10FF00 Type 2 diabetes mellitus with peripheral angiopathy
59253 C10FG00 Type 2 diabetes mellitus with arthropathy
37648 C109J11 Insulin treated non-insulin dependent diabetes mellitus
55075 C109411 Type II diabetes mellitus with ulcer
52303 C109000 Non-insulin-dependent diabetes mellitus with kidney comps
42762 C109612 Type 2 diabetes mellitus with retinopathy
24836 C109C12 Type 2 diabetes mellitus with nephropathy
45467 C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy
45919 C109212 Type 2 diabetes mellitus with neurological complications
50429 C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps
69278 C109E00 Non-insulin depend diabetes mellitus with diabetic cataract
40401 C109500 Non-insulin dependent diabetes mellitus with gangrene
43785 C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma
44779 C109E12 Type 2 diabetes mellitus with diabetic cataract
47816 C109H11 Type II diabetes mellitus with neuropathic arthropathy
55842 C109200 Non-insulin-dependent diabetes mellitus with neuro comps
18209 C109012 Type 2 diabetes mellitus with kidney complications
48192 C109E11 Type II diabetes mellitus with diabetic cataract
50225 C109011 Type II diabetes mellitus with kidney complications
62107 C109511 Type II diabetes mellitus with gangrene
65267 C10F300 Type 2 diabetes mellitus with multiple complications
65704 C109412 Type 2 diabetes mellitus with ulcer
43227 C10F311 Type II diabetes mellitus with multiple complications
46150 C109512 Type 2 diabetes mellitus with gangrene
64571 C109C11 Type II diabetes mellitus with nephropathy
66965 C109H12 Type 2 diabetes mellitus with neuropathic arthropathy
24693 C109G00 Non-insulin dependent diabetes mellitus with arthropathy
54899 C109F11 Type II diabetes mellitus with peripheral angiopathy
61071 C109D12 Type 2 diabetes mellitus with hypoglycaemic coma
67905 C109211 Type II diabetes mellitus with neurological complications
47409 C109B11 Type II diabetes mellitus with polyneuropathy
50527 C10FB11 Type II diabetes mellitus with polyneuropathy
57278 C10F011 Type II diabetes mellitus with kidney complications
59725 C109111 Type II diabetes mellitus with ophthalmic complications
60699 C109F12 Type 2 diabetes mellitus with peripheral angiopathy
62146 C109300 Non-insulin-dependent diabetes mellitus with multiple comps
72320 C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy
18143 C109G11 Type II diabetes mellitus with arthropathy
49869 C109G12 Type 2 diabetes mellitus with arthropathy
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50813 C109A11 Type II diabetes mellitus with mononeuropathy
56268 C109D11 Type II diabetes mellitus with hypoglycaemic coma
70316 C109112 Type 2 diabetes mellitus with ophthalmic complications
85991 C10FM11 Type II diabetes mellitus with persistent microalbuminuria
91646 C10F411 Type II diabetes mellitus with ulcer
93727 C10FE11 Type II diabetes mellitus with diabetic cataract
Table C.1. Co-morbidities codes
Medcode Read Code Read Term
Blindness
510 6689 Registered blind
8367 F49..00 Blindness and low vision
1990 F490.00 Blindness, both eyes
3851 F495000 Blindness, one eye, unspeciﬁed
10388 2B6A.11 O/E - blind R-eye
3852 2B7A.11 O/E - blind L-eye
33014 2B6B.00 O/E - R-eye completely blind
53955 F485z00 Colour blindness NOS
32044 SJ0z.11 Blindness - traumatic - NOS
33016 2B7B.00 O/E - L-eye completely blind
23742 F49z.11 Acquired blindness
32467 F4H7300 Cortical blindness
3438 E201100 Hysterical blindness
47956 F490z00 Blindness both eyes NOS
38000 F495A00 Acquired blindness, one eye
55108 F490000 Unspeciﬁed blindness both eyes
10868 F404100 Blind hypotensive eye
37086 F404200 Blind hypertensive eye
29387 F491000 One eye blind, one eye low vision
55436 F490100 Both eyes total visual impairment
51274 2B6S.00 O/E - pinhole R-eye completely blind
54513 2B7S.00 O/E - pinhole L-eye completely blind
104077 F49A.00 Blindness, monocular
42262 F490900 Acquired blindness, both eyes
54962 F491z00 One eye blind, one eye low vision NOS
104853 F497.00 Severe visual impairment, binocular
105206 F49B.00 Severe visual impairment, monocular
60401 F494.00 Legal blindness USA
67126 8F61.00 Blind rehabilitation
73508 ZN56800 Blind telephone user
(continued)
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98637 FyuL.00 [X]Visual disturbances and blindness
99504 F491100 Better eye: severe VI, Lesser eye: blind, unspeciﬁed
106329 9m08.00 Excluded from diabetic retinopathy screening as blind
63045 F495100 Lesser eye: total visual impairment, Better eye: unspeciﬁed
68391 F491500 Better eye: moderate VI, Lesser eye: blind, unspeciﬁed
Atrial Fibrillation
1664 G573000 Atrial ﬁbrillation
2212 G573.00 Atrial ﬁbrillation and ﬂutter
1268 G573200 Paroxysmal atrial ﬁbrillation
3757 3272 ECG: atrial ﬁbrillation
23437 G573z00 Atrial ﬁbrillation and ﬂutter NOS
96076 G573500 Persistent atrial ﬁbrillation
96277 G573400 Permanent atrial ﬁbrillation
35127 G573300 Non-rheumatic atrial ﬁbrillation
93460 14AR.00 History of atrial ﬂutter
Peripheral Vascular Disease
2760 G73zz00 Peripheral vascular disease NOS
3530 G73z.00 Peripheral vascular disease NOS
5943 G73..00 Other peripheral vascular disease
4325 G73yz00 Other speciﬁed peripheral vascular disease NOS
6356 7A4B000 Percutaneous transluminal angioplasty of femoral artery
2066 7A48z00 Other bypass of femoral artery or popliteal artery NOS
10827 7A44000 Percutaneous transluminal angioplasty of iliac artery
18060 7A48.14 Other bypass of femoral artery
2761 7A12100 Bypass bifurc aorta by anastom aorta to femoral artery NEC
24692 7A48.00 Other bypass of femoral artery or popliteal artery
29112 7A4B100 Percutaneous transluminal angioplasty of popliteal artery
12331 7A48.15 Other bypass of popliteal artery
8610 G76z000 Iliac artery occlusion
27580 7A48000 Bypass femoral artery by fem/pop art anast c prosthesis NEC
28030 7A48200 Bypass femoral artery by fem/pop art anast c vein graft NEC
27494 G74y300 Embolism and thrombosis of the iliac artery unspeciﬁed
15532 7A12300 Bypass bifurcation aorta by anastom aorta to iliac artery
21927 7A41.00 Other bypass of iliac artery
11766 7A47.16 Other emergency bypass of femoral artery
42640 7A48y00 Other bypass of femoral artery or popliteal artery OS
31723 7A28000 Percutaneous transluminal angioplasty of subclavian artery
28616 7A41100 Bypass iliac artery by iliac/femoral artery anastomosis NEC
38907 G73y.00 Other speciﬁed peripheral vascular disease
39776 7A47.14 Other emergency bypass of popliteal artery
41823 7A48600 Bypass femoral artery by fem/tib art anast c vein graft NEC
9099 7A47.00 Other emergency bypass of femoral artery or popliteal artery
45428 7A48C00 Bypass femoral artery by femoral/femoral art anastomosis NEC
29183 7A26000 Bypass of subclavian artery NEC
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42115 7A48D00 Bypass popliteal artery by pop/fem artery anastomosis NEC
24097 7A48300 Bypass popliteal artery by pop/pop a anast c vein graft NEC
37465 7A28100 Percutaneous transluminal angioplasty of brachial artery
36443 7A41300 Bypass iliac artery by femoral/femoral art anastomosis NEC
39877 7A48400 Bypass femoral artery by fem/tib art anast c prosthesis NEC
37546 7A26700 Bypass of brachial artery NEC
48700 7A48700 Bypass popliteal artery by pop/tib a anast c vein graft NEC
52357 7A41y00 Other speciﬁed other bypass of iliac artery
58191 7A26100 Bypass of axillary artery NEC
37787 7A48.12 Other bypass of common femoral artery
38921 7A41z00 Other bypass of iliac artery NOS
40732 7A48.16 Other bypass of superﬁcial femoral artery
60370 7A28C00 Percutaneous transluminal angioplasty of axillary artery
61974 7A48.11 Other bypass of femoral or popliteal artery by anastomosis
60465 7A48500 Bypass popliteal artery by pop/tib a anast c prosthesis NEC
32492 7A41900 Bypass common iliac artery by aorta/com iliac art anast NEC
55554 7A41B00 Bypass leg artery by aorta/com femoral art anastomosis NEC
65692 7A47y00 Other emergency bypass of femoral or popliteal artery OS
68320 7A47z00 Other emergency bypass of femoral or popliteal artery NOS
48939 7A47C00 Emerg bypass femoral artery by fem/fem art anastomosis NEC
66804 7A41C00 Bypass leg artery by aorta/deep femoral art anastomosis NEC
70922 7A47D00 Emerg bypass popliteal artery by pop/fem art anastomosis NEC
72448 7A41200 Emerg bypass iliac artery by femoral/femoral art anast NEC
48755 7A12000 Emerg bypass bifurc aorta by anast aorta to femoral artery
63238 7A47.13 Other emergency bypass of deep femoral artery
64555 7A48100 Bypass popliteal artery by pop/pop a anast c prosthesis NEC
66917 7A41600 Emerg bypass leg artery by aorta/com fem art anastomosis NEC
67982 7A48800 Bypass femoral artery by fem/peron a anast c prosthesis NEC
97606 7A47.15 Other emergency bypass of superﬁcial femoral artery
733 7A54000 Percutaneous transluminal angioplasty of artery NEC
5640 G70..00 Atherosclerosis
1318 G700.00 Aortic atherosclerosis
30296 7A1A000 Percutaneous transluminal balloon angioplasty of aorta
53675 7A48A00 Bypass femoral artery by fem/peron a anast c vein graft NEC
56429 P76z.00 Peripheral vascular system anomaly NOS
44528 SP12z00 Peripheral vascular complications of care NOS
66921 7A6H400 Percutaneous transluminal angioplasty of vascular graft
95430 7A56200 Percutaneous transluminal occlusion of artery
73961 Gyu7400 [X]Other speciﬁed peripheral vascular diseases
1517 G73z000 Intermittent claudication
6853 G73z011 Claudication
7975 16I..00 Claudication distance
1826 G73..12 Ischaemia of legs
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Stroke
1469 G66..00 Stroke and cerebrovascular accident unspeciﬁed
1298 G66..11 CVA unspeciﬁed
3149 G64z.00 Cerebral infarction NOS
5363 G64..11 CVA - cerebral artery occlusion
6116 G66..13 CVA - Cerebrovascular accident unspeciﬁed
6960 G61..11 CVA - cerebrovascular accid due to intracerebral haemorrhage
569 G64..12 Infarction - cerebral
7780 G667.00 Left sided CVA
12833 G668.00 Right sided CVA
6155 G64..13 Stroke due to cerebral arterial occlusion
6253 G66..12 Stroke unspeciﬁed
18604 G61..12 Stroke due to intracerebral haemorrhage
17322 G664.00 Cerebellar stroke syndrome
8443 G663.00 Brain stem stroke syndrome
9985 G64z200 Left sided cerebral infarction
10504 G64z300 Right sided cerebral infarction
36717 G640000 Cerebral infarction due to thrombosis of cerebral arteries
23671 G63y000 Cerebral infarct due to thrombosis of precerebral arteries
6228 G68X.00 Sequelae of stroke, not speciﬁed as haemorrhage or infarction
24446 G63y100 Cerebral infarction due to embolism of precerebral arteries
39344 G676000 Cerebral infarct due cerebral venous thrombosis, non-pyogenic
27975 G641000 Cerebral infarction due to embolism of cerebral arteries
53745 Gyu6400 [X]Other cerebral infarction
39403 G683.00 Sequelae of cerebral infarction
47607 L440.11 CVA - cerebrovascular accident in the puerperium
51759 G677000 Occlusion and stenosis of middle cerebral artery
31704 G677.00 Occlusion/stenosis cerebral arts not result cerebral infarct
65770 G677200 Occlusion and stenosis of posterior cerebral artery
57527 G677100 Occlusion and stenosis of anterior cerebral artery
56279 L440.12 Stroke in the puerperium
Myocardial infarction
241 G30..00 Acute myocardial infarction
14658 G30z.00 Acute myocardial infarction NOS
1677 G30..15 MI - acute myocardial infarction
10562 G307100 Acute non-ST segment elevation myocardial infarction
1678 G308.00 Inferior myocardial infarction NOS
1204 G30..14 Heart attack
12229 G30X000 Acute ST segment elevation myocardial infarction
2491 G30..12 Coronary thrombosis
14897 G301z00 Anterior myocardial infarction NOS
5387 G301.00 Other speciﬁed anterior myocardial infarction
12139 G300.00 Acute anterolateral infarction
8935 G302.00 Acute inferolateral infarction
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17872 G301100 Acute anteroseptal infarction
9507 G307000 Acute non-Q wave infarction
23892 G304.00 Posterior myocardial infarction NOS
7783 323..00 ECG: myocardial infarction
16408 G32..11 Healed myocardial infarction
14898 G305.00 Lateral myocardial infarction NOS
13571 G30..16 Thrombosis - coronary
29643 G303.00 Acute inferoposterior infarction
17689 G30..17 Silent myocardial infarction
46017 G30yz00 Other acute myocardial infarction NOS
18842 G35..00 Subsequent myocardial infarction
13566 G30..11 Attack - heart
32272 G38..00 Postoperative myocardial infarction
34803 G30y.00 Other acute myocardial infarction
29758 G30X.00 Acute transmural myocardial infarction of unspeciﬁc site
41221 G30y200 Acute septal infarction
23579 G310.00 Postmyocardial infarction syndrome
38609 G351.00 Subsequent myocardial infarction of inferior wall
63467 G306.00 True posterior myocardial infarction
32854 G30B.00 Acute posterolateral myocardial infarction
41835 G384.00 Postoperative subendocardial myocardial infarction
26972 3234 ECG:posterior/inferior infarct
68748 G38z.00 Postoperative myocardial infarction, unspeciﬁed
46112 G380.00 Postoperative transmural myocardial infarction anterior wall
46166 G35X.00 Subsequent myocardial infarction of unspeciﬁed site
62626 G30y100 Acute papillary muscle infarction
72562 G353.00 Subsequent myocardial infarction of other sites
96838 Gyu3400 [X]Acute transmural myocardial infarction of unspeciﬁed site
Congestive heart failure
241 G30..00 Acute myocardial infarction
14658 G30z.00 Acute myocardial infarction NOS
1677 G30..15 MI - acute myocardial infarction
10562 G307100 Acute non-ST segment elevation myocardial infarction
5904 792..00 Coronary artery operations
1678 G308.00 Inferior myocardial infarction NOS
1204 G30..14 Heart attack
12229 G30X000 Acute ST segment elevation myocardial infarction
2491 G30..12 Coronary thrombosis
14897 G301z00 Anterior myocardial infarction NOS
7442 7920200 Saphenous vein graft replacement of three coronary arteries
5387 G301.00 Other speciﬁed anterior myocardial infarction
12139 G300.00 Acute anterolateral infarction
8935 G302.00 Acute inferolateral infarction
11610 7920300 Saphenous vein graft replacement of fourþ coronary arteries
(continued)
Clinical Therapeutics
1832.e8 Volume 38 Number 8
Table C.1. (continued).
Medcode Read Code Read Term
17872 G301100 Acute anteroseptal infarction
7634 7920100 Saphenous vein graft replacement of two coronary arteries
9507 G307000 Acute non-Q wave infarction
10603 792z.00 Coronary artery operations NOS
23892 G304.00 Posterior myocardial infarction NOS
7783 323..00 ECG: myocardial infarction
16408 G32..11 Healed myocardial infarction
14898 G305.00 Lateral myocardial infarction NOS
13571 G30..16 Thrombosis - coronary
29643 G303.00 Acute inferoposterior infarction
17689 G30..17 Silent myocardial infarction
46017 G30yz00 Other acute myocardial infarction NOS
18842 G35..00 Subsequent myocardial infarction
13566 G30..11 Attack - heart
47788 7927 Other open operations on coronary artery
32272 G38..00 Postoperative myocardial infarction
9555 G33z500 Post infarct angina
34803 G30y.00 Other acute myocardial infarction
29758 G30X.00 Acute transmural myocardial infarction of unspeciﬁc site
41221 G30y200 Acute septal infarction
10209 7921200 Autograft replacement of three coronary arteries NEC
23579 G310.00 Postmyocardial infarction syndrome
42708 7921300 Autograft replacement of four of more coronary arteries NEC
19413 7921100 Autograft replacement of two coronary arteries NEC
38609 G351.00 Subsequent myocardial infarction of inferior wall
63467 G306.00 True posterior myocardial infarction
32854 G30B.00 Acute posterolateral myocardial infarction
41835 G384.00 Postoperative subendocardial myocardial infarction
45370 7922300 Allograft replacement of four or more coronary arteries
45886 7922200 Allograft replacement of three coronary arteries
31540 7924200 Revision of bypass for three coronary arteries
26972 3234 ECG:posterior/inferior infarct
67761 7923300 Prosthetic replacement of four or more coronary arteries
46276 G381.00 Postoperative transmural myocardial infarction inferior wall
55092 792C000 Replacement of coronary arteries using multiple methods
66236 7923200 Prosthetic replacement of three coronary arteries
57241 7922100 Allograft replacement of two coronary arteries
67554 7924100 Revision of bypass for two coronary arteries
68748 G38z.00 Postoperative myocardial infarction, unspeciﬁed
31519 7925100 Double implant of mammary arteries into coronary arteries
46112 G380.00 Postoperative transmural myocardial infarction anterior wall
46166 G35X.00 Subsequent myocardial infarction of unspeciﬁed site
62608 7926000 Double anastom thoracic arteries to coronary arteries NEC
62626 G30y100 Acute papillary muscle infarction
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66664 7923100 Prosthetic replacement of two coronary arteries
72562 G353.00 Subsequent myocardial infarction of other sites
96838 Gyu3400 [X]Acute transmural myocardial infarction of unspeciﬁc site
1430 G33..00 Angina pectoris
19542 662K000 Angina control - good
1431 G311.13 Unstable angina
13185 662K.00 Angina control
1344 G340.12 Coronary artery disease
7347 G311100 Unstable angina
8942 7929400 Insertion of coronary artery stent
28554 G33zz00 Angina pectoris NOS
7137 7920y00 Saphenous vein graft replacement of coronary artery OS
1414 G33z300 Angina on effort
4656 G311.11 Crescendo angina
12804 G33z700 Stable angina
25842 G33z.00 Angina pectoris NOS
15373 662K100 Angina control - poor
18118 G311400 Worsening angina
17054 7N41300 [SO]Coronary artery
18249 7920 Saphenous vein graft replacement of coronary artery
14782 662K200 Angina control - improving
15349 662Kz00 Angina control NOS
17307 G311200 Angina at rest
18889 G34z000 Asymptomatic coronary heart disease
19655 G311.14 Angina at rest
36854 G332.00 Coronary artery spasm
12986 G331.00 Prinzmetal's angina
22020 792B000 Endarterectomy of coronary artery NEC
42304 7929500 Insertion of drug-eluting coronary artery stent
8679 7920000 Saphenous vein graft replacement of one coronary artery
17133 G30A.00 Mural thrombosis
51515 7920z00 Saphenous vein graft replacement coronary artery NOS
9414 7921 Other autograft replacement of coronary artery
24888 7929 Other therapeutic transluminal operations on coronary artery
18125 G330000 Nocturnal angina
26863 G33z600 New onset angina
11048 G331.11 Variant angina pectoris
30421 G30..13 Cardiac rupture following myocardial infarction (MI)
34328 G311300 Refractory angina
31571 792y.00 Other speciﬁed operations on coronary artery
45960 8B27.00 Antianginal therapy
34965 792A.00 Diagnostic transluminal operations on coronary artery
28736 G30y000 Acute atrial infarction
40429 G301000 Acute anteroapical infarction
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39449 G312.00 Coronary thrombosis not resulting in myocardial infarction
44561 7921000 Autograft replacement of one coronary artery NEC
44585 792Bz00 Repair of coronary artery NOS
31556 7922 Allograft replacement of coronary artery
45809 G350.00 Subsequent myocardial infarction of anterior wall
55137 G311011 MI - myocardial infarction aborted
33620 792B.00 Repair of coronary artery NEC
61072 G311000 Myocardial infarction aborted
51043 ZRBN.00 Duke's coronary artery disease score
6182 7929y00 Other therapeutic transluminal op on coronary artery OS
29902 G330z00 Angina decubitus NOS
19402 7923 Prosthetic replacement of coronary artery
51702 7927400 Exploration of coronary artery
51507 7925300 Single anastomosis of mammary artery to coronary artery NEC
33718 7925000 Double anastomosis of mammary arteries to coronary arteries
55598 792C.00 Other replacement of coronary artery
41757 7927z00 Other open operation on coronary artery NOS
7609 7921z00 Other autograft replacement of coronary artery NOS
37719 7925y00 Connection of mammary artery to coronary artery OS
48767 7922z00 Allograft replacement of coronary artery NOS
61248 792Az00 Diagnostic transluminal operation on coronary artery NOS
66583 7929200 Percut translum inject therap subst to coronary artery NEC
93618 7929600 Percutaneous transluminal atherectomy of coronary artery
56905 792Ay00 Diagnostic transluminal operation on coronary artery OS
68139 7925400 Single implantation of mammary artery into coronary artery
61310 7921y00 Other autograft replacement of coronary artery OS
69247 792By00 Other speciﬁed repair of coronary artery
70755 792Cz00 Replacement of coronary artery NOS
52615 P6y7.00 Myocardial bridge of coronary artery
59423 7922y00 Other speciﬁed allograft replacement of coronary artery
60753 7926300 Single implantation thoracic artery into coronary artery NEC
67591 7926200 Single anastomosis of thoracic artery to coronary artery NEC
70111 7922000 Allograft replacement of one coronary artery
19193 7923z00 Prosthetic replacement of coronary artery NOS
39546 Gyu3000 [X]Other forms of angina pectoris
61592 7927200 Transection of muscle bridge of coronary artery
72780 7926z00 Connection of other thoracic artery to coronary artery NOS
92419 7923000 Prosthetic replacement of one coronary artery
93828 792Cy00 Other speciﬁed replacement of coronary artery
94783 792B100 Repair of rupture of coronary artery
95382 7927y00 Other speciﬁed other open operation on coronary artery
96804 7926 Connection of other thoracic artery to coronary artery
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Amputation
3245 7L08.00 Amputation of toe
434 7L05300 Amputation of ﬁnger NEC
3590 7L06400 Amputation below knee
3779 7L06200 Amputation above knee
3701 7L06.00 Amputation of leg
15071 7L08z00 Amputation of toe NOS
6955 14N4.00 H/O: limb amputation
21262 7L05200 Amputation of phalanx of ﬁnger
3781 SP16.00 Late amputation stump complication
1248 7L05100 Amputation of thumb
12526 7L0F500 Amputation of supernumerary ﬁnger NEC
3344 7L07.00 Amputation of foot
15010 7L06z00 Amputation of leg NOS
15915 7L08y00 Other speciﬁed amputation of toe
18935 7L04.00 Amputation of arm
27513 7L09.00 Operations on amputation stump
23359 SP16z00 Late amputation stump complication NOS
3780 7L09300 Revision coverage of amputation stump
33621 7L08100 Amputation of phalanx of toe
2361 7L06300 Amputation through knee
15170 7L07000 Amputation through ankle
31336 SA5..00 Traumatic amputation of toe(s)
16207 7L07z00 Amputation of foot NOS
6288 7L05.00 Amputation of hand
5289 SA8..00 Traumatic amputation of limb
28715 7L0L200 Amputation of supernumerary toe
20691 7L0F400 Amputation of duplicate thumb
29965 SP16200 Chronic infection of amputation stump
7044 7L09500 Excision neuroma amputation stump
33714 7L08300 Amputation lesser toe
28130 7L07300 Amputation through metatarsal bones
27488 7L09z00 Operation on amputation stump NOS
20751 SP16100 Neuroma of amputation stump
29351 7L04z00 Amputation of arm NOS
27366 7L04300 Amputation through forearm
20105 7L04200 Amputation above elbow
45763 7L05400 Amputation through phalanx of ﬁnger
32049 14N4100 H/O: lower limb amputation
31916 7L07012 Syme amputation of foot through ankle
33565 7L07212 Tarsometatarsal amputation
48492 7L08011 Amputation great toe
37958 7L07312 Ray transmetatarsal amputation
47889 7L07y00 Other speciﬁed amputation of foot
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Clinical Therapeutics
1832.e12 Volume 38 Number 8
Table C.1. (continued).
Medcode Read Code Read Term
27350 7L06000 Hindquarter amputation
69518 14N4Z00 H/O: limb amputation NOS
34646 7L05z00 Amputation of hand NOS
50589 7L06012 Gordon - Taylor hindquarter amputation
28868 7L09200 Shortening of amputation stump
51386 7L09y00 Other speciﬁed operation on amputation stump
42881 7L05y00 Other speciﬁed amputation of hand
40307 7L09000 Reamputation at higher level
54211 7L06412 Burgess amputation of leg below knee
51330 7L06y00 Other speciﬁed amputation of leg
50090 TB05.00 Amputation of limb(s) with complication, without blame
52202 7L04311 Amputation of arm below elbow
29405 SP16000 Late amputation stump complication, unspeciﬁed
73477 7L04y00 Other speciﬁed amputation of arm
54847 SP16400 Bony prominence in amputation stump
70129 14N4000 H/O: upper limb amputation
71110 7L06212 Amputation of leg through thigh
94132 SA50100 Traumatic amputation, greater toe
43365 7L09400 Drainage of amputation stump
51017 7L07311 Chopart midtarsal amputation
49808 7L04312 Krukenberg amputation of arm below elbow
60867 7L07z11 Hey amputation of foot
47940 7L06011 Ferre hindquarter amputation
52829 SyuKM00 [X]Other and unspeciﬁed amputation stump complications
90768 7P20000 Delivery of rehabilitation for amputation of limb
97313 SP16300 Necrosis of amputation stump
100328 7L05000 Amputation through wrist
52033 7L06014 King hindquarter amputation
97895 7L06411 Boyd amputation of leg below knee
100702 7L04400 Amputation through elbow
104068 Syu9F00 [X]Traumatic amputation of other parts of foot
104091 8D47600 Midfoot amputation prosthesis
105850 SP16500 Poorly shaped amputation stump
100835 7L06211 Kirk amputation of leg through thigh
Renal failure
1Z14.00 Chronic kidney disease stage 5
1Z1K.00 Chronic kidney disease stage 5 with proteinuria
1Z1L.00 Chronic kidney disease stage 5 without proteinuria
1Z1K.11 CKD stage 5 with proteinuria
1Z1L.11 CKD stage 5 without proteinuria
1Z13.00 Chronic kidney disease stage 4
1Z1J.00 Chronic kidney disease stage 4 without proteinuria
1Z1H.00 Chronic kidney disease stage 4 with proteinuria
1Z1H.11 CKD stage 4 with proteinuria
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Table C.1. (continued).
Medcode Read Code Read Term
1Z1J.11 CKD stage 4 without proteinuria
1Z16.00 Chronic kidney disease stage 3B
1Z1G.00 Chronic kidney disease stage 3B without proteinuria
1Z1F.00 Chronic kidney disease stage 3B with proteinuria
1Z1F.11 CKD stage 3B with proteinuria
1Z1G.11 CKD stage 3B without proteinuria
1Z1E.00 Chronic kidney disease stage 3A without proteinuria
1Z15.00 Chronic kidney disease stage 3A
1Z1D.00 Chronic kidney disease stage 3A with proteinuria
1Z1E.11 CKD stage 3A without proteinuria
1Z1D.11 CKD stage 3A with proteinuria
1Z1..00 Chronic renal impairment
K060.00 Renal impairment
K060.11 Impaired renal function
K08..00 Impaired renal function disorder
K08z.00 Impaired renal function disorder NOS
K08yz00 Other impaired renal function disorder NOS
K08y.00 Other impaired renal function disorder
K05..00 Chronic renal failure
K06..00 Renal failure unspeciﬁed
K04..00 Acute renal failure
K04z.00 Acute renal failure NOS
K050.00 End stage renal failure
7L1A.11 Dialysis for renal failure
K0D..00 End-stage renal disease
Kyu2.00 [X]Renal failure
SK05.00 Renal failure following crush syndrome
SP15412 Post operative renal failure
SP15400 Renal failure as a complication of care
K05..12 End stage renal failure
G222.00 Hypertensive renal disease with renal failure
K04y.00 Other acute renal failure
G233.00 Hypertensive heart and renal disease with renal failure
K043.00 Acute drug-induced renal failure
Q48y000 Congenital renal failure
7L1B.00 Placement ambulatory apparatus compensation renal failure
Kyu2000 [X]Other acute renal failure
Kyu2100 [X]Other chronic renal failure
7L1C.00 Placement other apparatus for compensation for renal failure
7L1Ay00 Other speciﬁed compensation for renal failure
SK05.11 Renal failure after crushing
L093.00 Renal failure following abortive pregnancy
7L1Az00 Compensation for renal failure NOS
7L1Cz00 Placement other apparatus- compensate for renal failure NOS
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Table C.1. (continued).
Medcode Read Code Read Term
7L1By00 Placement ambulatory apparatus- compensate renal failure OS
L393200 Post-delivery acute renal failure with postnatal problem
L393000 Post-delivery acute renal failure unspeciﬁed
L393100 Post-delivery acute renal failure - delivered with p/n prob
K044.00 Acute renal failure due to urinary obstruction
1Z12.00 Chronic kidney disease stage 3
1Z1C.00 Chronic kidney disease stage 3 without proteinuria
1Z1B.00 Chronic kidney disease stage 3 with proteinuria
D215000 Anaemia secondary to chronic renal failure
D215.00 Anaemia secondary to renal failure
PD1..11 Congenital cystic renal disease
SK08.00 Acute renal failure due to rhabdomyolysis
C345.00 Gout due to impairment of renal function
1Z1C.11 CKD stage 3 without proteinuria
1Z1B.11 CKD stage 3 with proteinuria
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